Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
18794 | 470 | 31.4 | 76% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
202 | 20434 | CLOPIDOGREL//PRASUGREL//ASPIRIN RESISTANCE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | ACT STUDY | Author keyword | 2 | 67% | 0% | 2 |
2 | ASPIRIN DOSE | Author keyword | 2 | 67% | 0% | 2 |
3 | ANTIOXIDANT DEFENSE MECHANISM | Author keyword | 1 | 50% | 0% | 2 |
4 | WEIL FDN | Address | 1 | 100% | 0% | 2 |
5 | REGULATORY MED BLOOD P SURE | Address | 1 | 27% | 1% | 4 |
6 | CLIN SCI MED EDUC | Address | 1 | 30% | 1% | 3 |
7 | ASPIRIN USE | Author keyword | 1 | 40% | 0% | 2 |
8 | GRP AUTON NERVOUS SYST | Address | 1 | 23% | 1% | 3 |
9 | PAUL FOSTER MED | Address | 1 | 21% | 1% | 3 |
10 | ASPIRIN PRIMARY PREVENTION | Author keyword | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ACT STUDY | 2 | 67% | 0% | 2 | Search ACT+STUDY | Search ACT+STUDY |
2 | ASPIRIN DOSE | 2 | 67% | 0% | 2 | Search ASPIRIN+DOSE | Search ASPIRIN+DOSE |
3 | ANTIOXIDANT DEFENSE MECHANISM | 1 | 50% | 0% | 2 | Search ANTIOXIDANT+DEFENSE+MECHANISM | Search ANTIOXIDANT+DEFENSE+MECHANISM |
4 | ASPIRIN USE | 1 | 40% | 0% | 2 | Search ASPIRIN+USE | Search ASPIRIN+USE |
5 | ASPIRIN PRIMARY PREVENTION | 1 | 50% | 0% | 1 | Search ASPIRIN+PRIMARY+PREVENTION | Search ASPIRIN+PRIMARY+PREVENTION |
6 | BEDTIME ADMINISTRATION | 1 | 50% | 0% | 1 | Search BEDTIME+ADMINISTRATION | Search BEDTIME+ADMINISTRATION |
7 | CHRONIC ISCHEMIC | 1 | 50% | 0% | 1 | Search CHRONIC+ISCHEMIC | Search CHRONIC+ISCHEMIC |
8 | CORONARY COMPUTED TOMOGRAPHIC | 1 | 50% | 0% | 1 | Search CORONARY+COMPUTED+TOMOGRAPHIC | Search CORONARY+COMPUTED+TOMOGRAPHIC |
9 | GLICEMIC CONTROL | 1 | 50% | 0% | 1 | Search GLICEMIC+CONTROL | Search GLICEMIC+CONTROL |
10 | GUIDELINE BASED INTERVENTION | 1 | 50% | 0% | 1 | Search GUIDELINE+BASED+INTERVENTION | Search GUIDELINE+BASED+INTERVENTION |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | COLLABORATIVE METAANALYSIS | 4 | 10% | 8% | 36 |
2 | ONGOING PHYSICIANS HEALTH | 2 | 67% | 0% | 2 |
3 | PRIMARY PREVENTION TRIALS | 2 | 67% | 0% | 2 |
4 | CARDIOVASCULAR SOCIETY GUIDELINES | 1 | 50% | 0% | 1 |
5 | CHINESE HERBAL NEPHROPATHY | 1 | 50% | 0% | 1 |
6 | NCDR PINNACLE REGISTRY | 1 | 50% | 0% | 1 |
7 | PLATELET CYCLOOXYGENASE | 1 | 12% | 1% | 5 |
8 | CORONARY PREVENTION | 0 | 33% | 0% | 1 |
9 | FIBRINOGEN PLASMA LEVELS | 0 | 33% | 0% | 1 |
10 | THROMBOSIS PREVENTION | 0 | 33% | 0% | 1 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
Effect of Aspirin on Vascular and Nonvascular Outcomes Meta-analysis of Randomized Controlled Trials | 2012 | 109 | 39 | 59% |
Aspirin Therapy in Primary Cardiovascular Disease Prevention A Position Paper of the European Society of Cardiology Working Group on Thrombosis | 2014 | 11 | 42 | 60% |
Aspirin in Primary Prevention of Cardiovascular Disease and Cancer: A Systematic Review of the Balance of Evidence from Reviews of Randomized Trials | 2013 | 18 | 36 | 64% |
Aspirin for the primary prevention of cardiovascular events in women and men - A sex-specific meta-analysis of randomized controlled trials | 2006 | 355 | 25 | 32% |
Aspirin in the Treatment and Prevention of Cardiovascular Disease: Past and Current Perspectives and Future Directions | 2013 | 12 | 18 | 50% |
The aspirin controversy in primary prevention | 2012 | 15 | 17 | 59% |
Aspirin: Its risks, benefits, and optimal use in preventing cardiovascular events | 2013 | 6 | 39 | 46% |
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus | 2010 | 21 | 52 | 38% |
Aspirin for Primary Prevention of Cardiovascular Disease Events | 2012 | 13 | 61 | 39% |
Aspirin for the Prevention of Cardiovascular Disease Systematic Review | 2010 | 3 | 7 | 86% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | WEIL FDN | 1 | 100% | 0.4% | 2 |
2 | REGULATORY MED BLOOD P SURE | 1 | 27% | 0.9% | 4 |
3 | CLIN SCI MED EDUC | 1 | 30% | 0.6% | 3 |
4 | GRP AUTON NERVOUS SYST | 1 | 23% | 0.6% | 3 |
5 | PAUL FOSTER MED | 1 | 21% | 0.6% | 3 |
6 | CHARLES MIDT BIOMED SCI | 1 | 50% | 0.2% | 1 |
7 | CHINLE COMPREHENS HLTH CARE IL | 1 | 50% | 0.2% | 1 |
8 | CLIN EPIDEMIOL SYST MED | 1 | 50% | 0.2% | 1 |
9 | DIABET LIFESTYLE DIS | 1 | 50% | 0.2% | 1 |
10 | ILLAWARRA MED HLTH | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000270277 | ASPIRIN RESISTANCE//PFA 100//THROMBOSTAT |
2 | 0.0000135688 | POLYPILL//CORONARY HEART DISEASE RISK FUNCTIONS//REGICOR |
3 | 0.0000132374 | 9 ALLYLPURINES//ANTIPLATELET COMPOUNDS//HAMILTON GEN HOSP CLIN UNIT |
4 | 0.0000122766 | TRANSIENT ISCHEMIC ATTACK//ABCD2 SCORE//TIA |
5 | 0.0000091663 | NSAIDS//COXIBS//ROFECOXIB |
6 | 0.0000082499 | SILENT MYOCARDIAL ISCHAEMIA//SILENT CORONARY ARTERY DISEASE//SILENT MYOCARDIAL ISCHEMIA |
7 | 0.0000068219 | IST MED INTERNA VASCOLARE//AALENS MODEL//ADJUSTED SURVIVAL |
8 | 0.0000060615 | CLOPIDOGREL//PRASUGREL//TICAGRELOR |
9 | 0.0000060159 | STATINS//LOW DENSITY LIPOPROTEIN CHOLESTEROL//ATORVASTATIN |
10 | 0.0000058745 | RUN IN PERIOD//THERAPEUTIC INFORMATION//RUN IN |